 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...63646566676869707172737475» |
- ||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA) (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=2609, Completed, Sponsor: Bayer
Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma (clinicaltrials.gov) - Jan 14, 2013
P=N/A, N=20, Completed, Sponsor: University of Luebeck
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date, Combination therapy: Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) (clinicaltrials.gov) - Jan 10, 2013
P4, N=120, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Initiation date: Jun 2012 --> Dec 2012
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) (clinicaltrials.gov) - Jan 10, 2013
P2/3, N=261, Completed, Sponsor: Diabetic Retinopathy Clinical Research Network
Initiation date: Jun 2012 --> Dec 2012 N=136 --> 261
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Combination therapy: Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) (clinicaltrials.gov) - Jan 10, 2013
P4, N=120, Recruiting, Sponsor: Novartis Pharmaceuticals
N=136 --> 261 Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Jan 10, 2013
P3, N=316, Active, not recruiting, Sponsor: Diabetic Retinopathy Clinical Research Network
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 (clinicaltrials.gov) - Jan 10, 2013
P0, N=11, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) (clinicaltrials.gov) - Jan 10, 2013
P2/3, N=261, Completed, Sponsor: Diabetic Retinopathy Clinical Research Network
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Combination therapy, Monotherapy: Lucedex: A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD (clinicaltrials.gov) - Dec 17, 2012
P1/2, N=40, Completed, Sponsor: Subhransu K. Ray, M.D., Ph.D.
Active, not recruiting --> Completed Recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: HD-LIPT: High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia (clinicaltrials.gov) - Dec 11, 2012
P2, N=6, Completed, Sponsor: Eye Center of Northern Colorado, P.C.
Recruiting --> Completed Recruiting --> Completed
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR) (clinicaltrials.gov) - Dec 10, 2012
P3, N=1097, Completed, Sponsor: Genentech
Recruiting --> Completed Initiation date: Apr 2009 --> Jul 2009
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: T-REX: Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab (clinicaltrials.gov) - Dec 10, 2012
P3, N=60, Active, not recruiting, Sponsor: Charles C Wykoff, PhD, MD
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR) (clinicaltrials.gov) - Dec 10, 2012
P3, N=1097, Completed, Sponsor: Genentech
Initiation date: Apr 2009 --> Jul 2009 Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial: Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Dec 9, 2012
P1/2, N=30, Completed, Sponsor: University of Sao Paulo
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: LUDIC: A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema (clinicaltrials.gov) - Dec 5, 2012
P4, N=394, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=500 --> 394
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: LUDIC: A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema (clinicaltrials.gov) - Dec 5, 2012
P4, N=394, Completed, Sponsor: Novartis Pharmaceuticals
N=500 --> 394 Recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Surgery: OCTOPUS: Use of Ranibizumab With Mitomycin C During Trabeculectomy (clinicaltrials.gov) - Dec 3, 2012
P=N/A, N=30, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Completed N=10 --> 30
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) (clinicaltrials.gov) - Nov 25, 2012
P1, N=8, Terminated, Sponsor: David M. Brown, M.D.
N=10 --> 30 N=20 --> 8
- | Fumena (vorolanib) / Tyrogenex
Enrollment open: Pilot Study of X-82 in Patients With Wet AMD (clinicaltrials.gov) - Nov 11, 2012
P1/2, N=20, Recruiting, Sponsor: Xcovery Vision, LLC
N=20 --> 8 Not yet recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Ranibizumab and the Risk of Arterial Thromboembolic Events (clinicaltrials.gov) - Oct 29, 2012
P4, N=380, Completed, Sponsor: Ural State Medical Academy
Not yet recruiting --> Recruiting N=540 --> 380
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Ensayo cl (EUDRACT) - Oct 28, 2012
P4, N=166, Ongoing, Sponsor: Sociedad Espa
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: LUCAS (Lucentis Compared to Avastin Study) (clinicaltrials.gov) - Oct 24, 2012
P4, N=420, Active, not recruiting, Sponsor: Ullevaal University Hospital
N=540 --> 380 Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration (clinicaltrials.gov) - Oct 23, 2012
P=N/A, N=12, Active, not recruiting, Sponsor: Oraya Therapeutics, Inc.
Recruiting --> Active, not recruiting Initiation date: Mar 2012 --> Aug 2012
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: FVF4140S: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy (clinicaltrials.gov) - Oct 23, 2012
P1/2, N=18, Completed, Sponsor: Manhattan Eye, Ear & Throat Hospital
Initiation date: Mar 2012 --> Aug 2012 N=40 --> 18
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration (clinicaltrials.gov) - Oct 23, 2012
P=N/A, N=12, Active, not recruiting, Sponsor: Oraya Therapeutics, Inc.
N=40 --> 18 Not yet recruiting --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: FVF4140S: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy (clinicaltrials.gov) - Oct 23, 2012
P1/2, N=18, Completed, Sponsor: Manhattan Eye, Ear & Throat Hospital
Not yet recruiting --> Active, not recruiting Recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: NAION: Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy (clinicaltrials.gov) - Oct 21, 2012
P1, N=2, Completed, Sponsor: University of Colorado, Denver
Recruiting --> Completed N=15 --> 2
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO (clinicaltrials.gov) - Oct 21, 2012
P4, N=180, Recruiting, Sponsor: Novartis Pharmaceuticals
N=15 --> 2 Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial, Monotherapy: WAVE: Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion (clinicaltrials.gov) - Oct 17, 2012
P4, N=30, Recruiting, Sponsor: Charles C Wykoff, PhD, MD
- Lucentis (ranibizumab) / Roche, Novartis
Trial termination: Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) (clinicaltrials.gov) - Oct 14, 2012
P1, N=8, Terminated, Sponsor: David M. Brown, M.D.
Not yet recruiting --> Recruiting Recruiting --> Terminated; The collaborator, Genentech, stopped supplying the study drug to the site.
- Lucentis (ranibizumab) / Roche, Novartis
Trial termination: A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial) (clinicaltrials.gov) - Oct 14, 2012
P1/2, N=46, Terminated, Sponsor: David M. Brown, M.D.
Recruiting --> Terminated; The collaborator, Genentech, stopped supplying the study drug to the site. Active, not recruiting --> Terminated; The last remaining subject withdrew consent because the collaborator Genentech stopped supplying study drug.
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration (clinicaltrials.gov) - Oct 8, 2012
P=N/A, N=75, Active, not recruiting, Sponsor: National Eye Institute (NEI)
Active, not recruiting --> Terminated; The last remaining subject withdrew consent because the collaborator Genentech stopped supplying study drug. Recruiting --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial completion, Combination therapy: Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration (clinicaltrials.gov) - Oct 8, 2012
P4, N=31, Completed, Sponsor: Oklahoma State University Center for Health Sciences
Recruiting --> Active, not recruiting Recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments (clinicaltrials.gov) - Oct 2, 2012
P1, N=40, Completed, Sponsor: Clement K. Chan
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial completion: Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov) - Sep 27, 2012
P3, N=277, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial withdrawal: Ranibizumab for Neovascularization in Sickle Cell Retinopathy (clinicaltrials.gov) - Sep 24, 2012
P1, N=0, Withdrawn, Sponsor: Kresge Eye Institute
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial (clinicaltrials.gov) - Sep 17, 2012
P1, N=7, Completed, Sponsor: Johns Hopkins University
Recruiting --> Withdrawn N=10 --> 7
- ||| iSONEP (sonepcizumab) / Pfizer, Apollo Endosurgery
Trial initiation date, Monotherapy: Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD (clinicaltrials.gov) - Sep 16, 2012
P2, N=160, Recruiting, Sponsor: Lpath, Inc.
N=10 --> 7 Initiation date: Sep 2011 --> Aug 2012
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: REPAIR: Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen (clinicaltrials.gov) - Sep 16, 2012
P2, N=65, Completed, Sponsor: Novartis
Initiation date: Sep 2011 --> Aug 2012 Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: LuRVO: Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab (clinicaltrials.gov) - Sep 10, 2012
P=N/A, N=24, Completed, Sponsor: Glostrup University Hospital, Copenhagen
Active, not recruiting --> Completed N=30 --> 24
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: LuRVO: Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab (clinicaltrials.gov) - Sep 10, 2012
P=N/A, N=24, Completed, Sponsor: Glostrup University Hospital, Copenhagen
N=30 --> 24 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial suspension: Bevacizumab Versus Ranibizumab for Diabetic Retinopathy (clinicaltrials.gov) - Sep 5, 2012
P3, N=60, Suspended, Sponsor: Medical University of Vienna
Active, not recruiting --> Completed Recruiting --> Suspended
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: Bevacizumab Versus Ranibizumab for Diabetic Retinopathy (clinicaltrials.gov) - Sep 5, 2012
P3, N=60, Suspended, Sponsor: Medical University of Vienna
Recruiting --> Suspended Initiation date: Jan 2007 --> Jun 2008
- |||| iSONEP (sonepcizumab) / Pfizer, Apollo Endosurgery
Enrollment open, Monotherapy: Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD (clinicaltrials.gov) - Aug 28, 2012
P2, N=160, Recruiting, Sponsor: Lpath, Inc.
Initiation date: Jan 2007 --> Jun 2008 Active, not recruiting --> Recruiting
- | Fumena (vorolanib) / Tyrogenex
New P1/2 trial: Pilot Study of X-82 in Patients With Wet AMD (clinicaltrials.gov) - Aug 27, 2012
P1/2, N=20, Recruiting, Sponsor: Xcovery Vision, LLC
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing (clinicaltrials.gov) - Aug 26, 2012
P4, N=44, Completed, Sponsor: University Health Network, Toronto
Active, not recruiting --> Recruiting Not yet recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis (clinicaltrials.gov) - Aug 19, 2012
P4, N=20, Not yet recruiting, Sponsor: Osias Francisco de Souza
- Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
New P4 trial: Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) - Aug 14, 2012
P4, N=10, Not yet recruiting, Sponsor: Federal University of S
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye (clinicaltrials.gov) - Aug 8, 2012
P3, N=10, Completed, Sponsor: Queen's University
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: LERM: Treatment of Epiretinal Membranes With Ranibizumab (clinicaltrials.gov) - Jul 30, 2012
P=N/A, N=11, Completed, Sponsor: Queen's University
Not yet recruiting --> Completed Active, not recruiting --> Completed